⚠ Evidence warning: Clinical trials or other evidence do not support the claim that kava relaxes skeletal muscle and relieves spasm, back pain, fibromyalgia, tension-type headache, bruxism and post-exercise muscle tension without the strength-impairing or sedating effects of prescription muscle relaxants. This page keeps it as a report of what people, websites or other media say.
Kava for Muscle Relaxation
Beyond its better-known anxiolytic and sleep effects, kava is described as a skeletal muscle relaxant — an effect that traditional Polynesian, Melanesian, and Micronesian cultures recognized millennia before any mechanism was studied. The mechanism proposed is voltage-gated sodium channel blockade by the kavalactones: in laboratory studies kavain and methysticin blocked sodium channels in rat brain cells in a voltage-dependent (not use-dependent) way, and whole kava paralysed mouse and frog muscle preparations by mechanisms the researcher likened to local anaesthetics. Users and practitioners describe reduced muscle tone, relief of spasm, and less post-exercise muscle tension — without the strength-impairing or sedating effects they associate with conventional centrally-acting muscle relaxants like cyclobenzaprine and methocarbamol; no human trial has measured these muscle outcomes. This deep-dive walks through the sodium-channel mechanism, the traditional ceremonial context, the comparison to baclofen for spasticity and to skeletal muscle relaxants for back pain, and the emerging use of kava as an adjunct in fibromyalgia and tension-type headache.
Table of Contents
- Traditional Pacific Ceremonial Context
- Voltage-Gated Sodium Channel Blockade
- Kavain and Dihydrokavain as Principal Relaxants
- Kava versus Baclofen for Spasticity
- Kava versus Cyclobenzaprine and Methocarbamol for Back Pain
- Fibromyalgia and Chronic Widespread Pain
- Tension-Type Headache
- Post-Exercise Muscle Tension
- Temporomandibular Joint Dysfunction and Bruxism
- Amounts Used in Trials and Described in Practice
- Liver Safety Warnings From Regulators
- Key Research Papers
- Connections
- Featured Videos
Traditional Pacific Ceremonial Context
Kava's use as a muscle relaxant predates by millennia any modern understanding of voltage-gated sodium channels. Across Polynesia, Melanesia, and Micronesia, traditional kava ceremonies followed a pattern that reflected an intuitive understanding of the herb's skeletal muscle relaxant effect. Participants would consume kava in a seated position; the characteristic physical sensation included a gradual softening of skeletal muscle tone, particularly in the shoulders, jaw, and lower back, followed by a feeling of relaxed but mentally clear sociability. The ceremonies were often associated with discussions of community matters, dispute resolution, and political negotiation — contexts in which physical relaxation and reduced fight-or-flight tension favored productive discourse.
Anthropological documentation of kava ceremonies dates to the earliest European contact with the Pacific. James Cook visited Tonga in 1773 and again in 1777. Subsequent ethnographic work by Margaret Mead in Samoa, Bronislaw Malinowski in Melanesia, and many others through the 20th century has consistently identified physical relaxation as a core component of the traditional kava experience, distinct from intoxication or sedation.
The traditional use as a muscle relaxant also extended beyond ceremonial contexts. Fijian and Vanuatuan traditional medicine documents kava root preparations applied to localized muscle injury or used for chronic muscle tension. Specific cultivars are associated with stronger or weaker muscle-relaxant effect — cultivars high in dihydrokavain and kavain are described as more "heady" and physically relaxing, while cultivars higher in yangonin are described as more cognitively or mood-active.
The modern pharmacological mapping of these traditional categories onto specific kavalactone profiles is an ongoing area of kava research.
Voltage-Gated Sodium Channel Blockade
The principal molecular mechanism proposed for kava's skeletal muscle-relaxant effect is blockade of voltage-gated sodium channels (Nav) by kavain and dihydrokavain. Voltage-gated sodium channels are the molecular machines responsible for the rising phase of the action potential in excitable cells; they open in response to membrane depolarization, allow sodium influx that further depolarizes the membrane, and then rapidly inactivate to allow repolarization. Blockade of these channels reduces the excitability of the cell.
The same class of drugs — voltage-gated sodium channel blockers — is used clinically for several distinct purposes:
- Local anesthesia — lidocaine, bupivacaine, procaine block peripheral nerve sodium channels to prevent pain signal propagation
- Antiarrhythmic therapy — Class I antiarrhythmics (quinidine, lidocaine systemic, flecainide) block cardiac sodium channels to suppress ectopic ventricular activity
- Anticonvulsant therapy — phenytoin, carbamazepine, lamotrigine, oxcarbazepine block neuronal sodium channels to suppress seizure spread
- Skeletal muscle — several anticonvulsants at higher concentrations dampen skeletal muscle action potential generation; for kava, the only muscle data come from laboratory preparations of mouse and frog muscle (Singh 1983), not from people
The use-dependent nature of voltage-gated sodium channel blockade by these drugs is functionally important: the drugs preferentially block channels that are repeatedly opening, with less effect on channels at rest. This means a hyperactive system (a contracting muscle, a seizing neuron, an arrhythmic heart) is more affected than a resting system — the drugs reduce pathological excitability while leaving normal function relatively intact.
The kavalactones did not show this use-dependence in the patch-clamp study that tested it. In rat hippocampal brain cells, kavain and methysticin at 1–400 micromolar rapidly and reversibly reduced sodium currents, and the block grew stronger at more positive membrane voltages, but the compounds “did not demonstrate use-dependent properties at 10 Hz stimulation”; the authors explained the block by binding to resting closed and inactivated channels — a voltage-dependent rather than use-dependent block (Magura 1997). That study used brain cells, not muscle fibres. Users describe a gentle reduction in chronic muscle tension and spasm without loss of normal muscle strength or motor coordination; no trial has measured this.
The rest of the laboratory work is also in animal tissue, none of it in people. Kavain reduced both calcium and sodium currents in nerve-root cells (dorsal root ganglion cells) from newborn rats (Schirrmacher 1999). Kavain, dihydrokavain and dihydromethysticin inhibited binding at receptor site 2 of the voltage-gated sodium channel in a binding assay (Friese 1998). In mouse diaphragm and frog muscle preparations, whole kava paralysed the muscle, depressed the nerve-to-muscle signals, and slowed and depressed directly triggered muscle action potentials; the researcher concluded that kava “causes paralysis by mechanisms similar to local anaesthetics” (Singh 1983). We found no study comparing kavain's effect on the skeletal-muscle and heart forms of the sodium channel.
Kavain and Dihydrokavain as Principal Relaxants
Within the six-kavalactone class, kavain and dihydrokavain are the two principal contributors to the skeletal muscle-relaxant effect. The two compounds differ in molecular structure (dihydrokavain is the saturated form, with a single bond replacing kavain's alpha-beta double bond) and in pharmacokinetic profile (dihydrokavain has longer duration of action).
The functional consequences:
- Kavain — faster onset, shorter duration; the principal contributor to acute muscle-relaxant effect within 30–60 minutes of dosing
- Dihydrokavain — slower onset, longer duration; the principal contributor to sustained muscle relaxation over 4–6 hours
The other four kavalactones contribute less directly to muscle relaxation:
- Methysticin and dihydromethysticin — methysticin reduced sodium currents in rat brain cells alongside kavain (Magura 1997), and dihydromethysticin inhibited sodium-channel binding (Friese 1998); laboratory binding studies of kava pyrones found only weak activity at gamma-aminobutyric acid-A (GABA-A) binding sites and none at GABA-B sites (Davies 1992); any muscle effect is described as indirect, through anxiety relief and sleep
- Yangonin and desmethoxyyangonin — principally MAO-B inhibitor activity and mood effects; minimal direct muscle action
The cultivar-specific chemotype variation means different kava products will have different muscle-relaxant profiles. Cultivars high in kavain (such as Vanuatu Borogu and Tongan cultivars) tend to be subjectively more "heady" and physically relaxing; cultivars higher in methysticin and dihydromethysticin (such as some Fijian cultivars) tend to be more sedating.
Kava versus Baclofen for Spasticity
Baclofen is the conventional pharmacological treatment for spasticity associated with spinal cord injury, multiple sclerosis, cerebral palsy, and severe stroke. It is a gamma-aminobutyric acid-B receptor agonist that acts on spinal motor neurons to reduce alpha motor neuron excitability. Despite a different molecular target, the clinical effect overlaps with that of kava in some applications.
Mechanism Comparison
- Baclofen — central nervous system gamma-aminobutyric acid-B agonist at spinal cord; reduces alpha motor neuron firing rate
- Kava (kavain, dihydrokavain) — voltage-gated sodium channel blocker in laboratory studies of rat nerve cells and of mouse and frog muscle; binding studies found only weak GABA-A activity (Davies 1992); its effect on central drive and muscle excitability has not been measured in people
Clinical Profile Comparison
- Severity of effect — baclofen is a substantially stronger muscle relaxant for severe spasticity. Kava is a much milder relaxant.
- Cognitive impact — baclofen produces meaningful sedation, cognitive blunting, and fatigue, particularly at clinical doses for severe spasticity. Kava is not free of cognitive effects: in the largest kava trial (171 participants, 16 weeks), poorer memory occurred more frequently in the kava group than on placebo (36 versus 23) (Sarris 2020).
- Use case — baclofen for severe neurological spasticity; kava is used, on practitioner and user reports rather than trials, for mild chronic muscle tension, post-exercise muscle tension, anxiety-related muscle tension, and as adjunct in fibromyalgia or tension-type headache
- Withdrawal — baclofen produces a potentially severe withdrawal syndrome (seizures, rhabdomyolysis, hyperthermia) if discontinued abruptly after chronic high-dose use. Kava does not.
Kava is not a replacement for baclofen in true neurological spasticity. Practitioners describe it as an adjunct or alternative for the much more common pattern of mild-to-moderate chronic muscle tension; no trial has tested this.
Kava versus Cyclobenzaprine and Methocarbamol for Back Pain
Cyclobenzaprine, methocarbamol, carisoprodol, tizanidine, and metaxalone are commonly prescribed for acute low back pain and other musculoskeletal complaints. The evidence base for these "centrally acting muscle relaxants" is mixed: short-term symptomatic benefit is documented, but their mechanism is largely sedation rather than true muscle relaxation per se, and the side-effect profile is substantial.
Conventional Muscle Relaxants — Common Problems
- Cyclobenzaprine — structurally a tricyclic antidepressant; substantial anticholinergic effect (dry mouth, urinary retention, constipation, cognitive blunting); long half-life produces next-day grogginess; abuse potential exists but limited
- Methocarbamol — mechanism poorly understood; principally sedative; modest effect in trials
- Carisoprodol — metabolized to meprobamate; meaningful sedation, abuse potential, and dependence; Schedule IV in the US
- Tizanidine — alpha-2 agonist similar to clonidine; hypotension, drowsiness, dry mouth; hepatotoxicity reported
Kava as Alternative
For acute musculoskeletal pain, proponents describe kava as offering:
- Sodium channel blockade, seen in laboratory animal tissue, rather than purely central sedation
- No anticholinergic effect; in the largest kava trial, however, poorer memory and tremor/shakiness occurred more frequently on kava than on placebo (Sarris 2020)
- No abuse potential or controlled substance status
- Concurrent anxiolytic effect (which is often desired in acute pain states where anxiety amplifies the pain experience)
We found no trial of kava in acute musculoskeletal back pain. The argument is mechanistic and based on extrapolation from the broader kava literature plus the practical experience of integrative pain medicine practitioners. Patients who have tried both conventional muscle relaxants and kava commonly report the kava experience as more functional and less impairing.
For broader chronic pain management see our Chronic Pain page.
Fibromyalgia and Chronic Widespread Pain
Fibromyalgia is a chronic pain syndrome characterized by widespread musculoskeletal pain, persistent muscle tension, fatigue, cognitive complaints (fibro-fog), and frequently comorbid anxiety, depression, and sleep disturbance. The pathophysiology is incompletely understood but involves central sensitization (amplified central nervous system pain processing) plus chronic upregulation of skeletal muscle tone. The condition is notoriously difficult to treat; conventional pharmacotherapy (pregabalin, duloxetine, milnacipran) provides modest benefit at best for most patients.
Kava's pharmacological profile is unusually well-matched to the fibromyalgia symptom complex:
- Skeletal muscle tone reduction — addresses the chronic muscle tension component
- Anxiolytic effect — addresses the comorbid anxiety that amplifies fibromyalgia pain
- Sleep improvement — addresses the non-restorative sleep that is a core fibromyalgia feature and itself contributes to the pain
- Mood support — addresses comorbid depression
- Cognitive effects — relevant in patients already affected by fibro-fog; in the largest kava trial, poorer memory occurred more frequently on kava than on placebo (Sarris 2020)
We found no randomized controlled trial (RCT) of kava in fibromyalgia. The use comes from integrative pain medicine practice, where practitioners describe adding it as an adjunct to whatever conventional therapy a fibromyalgia patient is using, and report patient-described improvement in tender point soreness, sleep quality, and morning stiffness.
Many fibromyalgia patients take duloxetine, pregabalin, or other agents with sedative or liver effects, and many take acetaminophen chronically. The concerns raised for combining kava with these are additive sedation and added stress on the liver: the US Food and Drug Administration's 2002 advisory on kava and severe liver injury singled out people with liver disease or liver problems and people taking drugs that can affect the liver (see Liver Safety Warnings From Regulators).
Tension-Type Headache
Tension-type headache is the most common headache type, affecting more than 40% of adults at some point and producing chronic daily headache in approximately 3% of the population. The pathophysiology involves sustained pericranial muscle contraction (frontalis, occipitalis, temporalis, sternocleidomastoid, upper trapezius) combined with central sensitization and stress.
The conventional management ladder for tension-type headache is acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and tricyclic antidepressants (amitriptyline) for chronic cases. Kava's muscle-relaxant and anxiolytic effects produce a profile potentially well-suited to tension-type headache prevention and acute management:
- Direct effect on pericranial muscle tension — through the sodium channel mechanism discussed above
- Anxiolytic effect — addresses the stress trigger
- Sleep facilitation — addresses the sleep deprivation that frequently triggers tension headache
- No medication overuse headache risk — unlike acetaminophen and triptans, kava does not appear to produce the medication overuse headache phenomenon
We found no randomized controlled trial of kava in tension-type headache; the case rests on the laboratory mechanism and on practitioners' experience. Practitioners describe adding kava for chronic tension headache in people who have not done well on tricyclic antidepressant prophylaxis; the liver-injury reports described below apply to this use as to any other.
Post-Exercise Muscle Tension
A common subclinical use of kava among athletes and physically active adults is for post-exercise muscle tension and recovery. The reasoning offered is that high-intensity exercise produces elevated muscle tone, accumulated lactate and metabolic byproducts, and central sympathetic activation that can interfere with sleep and recovery. Kava's peripheral muscle-relaxant effect plus central anxiolysis addresses both the muscular and sympathetic components.
Use patterns described by users (not tested in trials):
- Evening post-workout dose — 120–180 mg kavalactones taken 1–2 hours after evening training or competition, for muscle relaxation and sleep onset
- Post-tournament recovery — daily use for 3–7 days following intense multi-day competition
- Combined with magnesium — many users combine kava with magnesium glycinate or threonate for synergistic muscle relaxation and report the combination as generally well tolerated
The only controlled kava study we found in people in hard physical training was a 2024 placebo-controlled crossover study of 15 healthy, physically fit young men in a rigorous two-a-day preparation class for special operations forces. Two weeks of kavalactones left cortisol, sleep and mood unchanged; the study reported a higher score for the motivation to expend energy (“Move”), and it did not measure muscle tension or recovery (Smith 2024).
Kava is not on the WADA prohibited list (status as of 2026). Kava combined with nonsteroidal anti-inflammatory drugs (common post-exercise) is described as an added liver risk; the FDA's 2002 kava advisory singled out people taking drugs that can affect the liver.
For broader nutritional support of muscle recovery see our Glutamine page and Magnesium page.
Temporomandibular Joint Dysfunction and Bruxism
Temporomandibular joint (TMJ) dysfunction and nocturnal bruxism (teeth grinding) are common conditions characterized by chronic involuntary contraction of the masseter, temporalis, and pterygoid muscles. The complaints often include morning jaw soreness, headache, sleep disturbance for both the patient and the bed partner, and progressive tooth wear.
Conventional therapy includes occlusal splints (dental nightguards), botulinum toxin injection into the masseter and temporalis, behavioral therapy, and pharmacological agents (low-dose tricyclic antidepressants, gabapentin, sometimes muscle relaxants). The relevant mechanism for kava in this context is the masticatory muscle relaxation produced by the kavalactones' sodium channel blockade, plus the central anxiolytic effect on the stress and anxiety components that drive nocturnal bruxism.
We found no trial of kava in bruxism or temporomandibular joint dysfunction. Practitioners describe using kava as an adjunct to occlusal splint therapy, typically 60–120 mg kavalactones taken at bedtime alongside whatever splint or other therapy is in use, and report patient-described reduction in morning jaw soreness, fewer headache mornings, and bed partner-reported reduction in audible grinding.
Amounts Used in Trials and Described in Practice
No trial has tested kava for muscle relaxation, so there is no trial dose for it. The largest controlled kava trial gave 171 participants with generalised anxiety disorder an aqueous extract of dried kava root, standardised to 120 mg of kavalactones twice a day, or placebo for 16 weeks. Kava was no better than placebo for anxiety. Poorer memory (36 versus 23) and tremor/shakiness (36 versus 23) occurred more frequently in the kava group, and liver function test abnormalities were significantly more frequent on kava, although no participant met criteria for herb-induced liver injury (Sarris 2020). The amounts below are those described in practice, not tested in trials.
Amounts Described for Acute Muscle Tension or Spasm
- Single amounts described: 120–240 mg kavalactones, with effect reported within 30–45 minutes and lasting 4–6 hours
- Practitioners describe combining it with localized heat or topical magnesium
Amounts Described for Chronic Muscle Tension (Tension Headache, Fibromyalgia Adjunct)
- 120–180 mg kavalactones daily, divided into two doses (morning and evening) or a single bedtime dose
- Effects described as building over 1–2 weeks of consistent use
- Practice patterns include periodic 1-week breaks every 4–6 weeks
Cultivars and Muscle Effect
- Cultivars with higher kavain and dihydrokavain content are described as producing a stronger muscle-relaxant effect
- Vanuatu Borogu, Melomelo, and several Tongan and Fijian cultivars are described as more physically relaxing
Product Form
- Aqueous extract (traditional cold-water preparation, freeze-dried aqueous powder, or instant kava): the largest controlled trial used an aqueous root extract and still found liver function test abnormalities significantly more often on kava than on placebo, although no participant met criteria for herb-induced liver injury (Sarris 2020)
- Encapsulated kavalactone-rich extracts are also sold
- Acetonic and ethanolic extracts are described as a concern unless their flavokavain B and pipermethystine content is documented
Combinations
- Magnesium glycinate or threonate 300–500 mg — synergistic muscle relaxation through different mechanism (N-methyl-D-aspartate (NMDA) receptor and calcium channel modulation)
- Passionflower — mild synergistic gamma-aminobutyric acid-A effect
- Valerian — synergistic gamma-aminobutyric acid (GABA) effect; used at bedtime specifically
- Combinations described as risky — cyclobenzaprine, baclofen, or benzodiazepines (additive central effects), alcohol (additive liver and central nervous system (CNS) effects), and statins (additive liver risk); the FDA's 2002 kava advisory singled out people taking drugs that can affect the liver
For broader context on natural muscle and pain management see our Willow Bark page and Turmeric page.
Liver Safety Warnings From Regulators
On March 25, 2002 the US Food and Drug Administration (FDA) advised consumers of the potential risk of severe liver injury associated with kava-containing dietary supplements. Kava products had been associated with liver-related injuries — including hepatitis, cirrhosis, and liver failure — in over 25 reports of adverse events in other countries, and four patients required liver transplants. In the US, the FDA had received a report of a previously healthy young woman who required a liver transplant, as well as several reports of liver-related injuries. Regulators in Germany, Switzerland, France, Canada, and the United Kingdom had taken action ranging from warning consumers to removing kava products from the market. The FDA noted that liver damage appears to be rare, and singled out people who have liver disease or liver problems and people taking drugs that can affect the liver (FDA 2002).
The advisory lists jaundice (yellowing of the skin or whites of the eyes) and brown urine as symptoms of serious liver disease, and nausea, vomiting, light-colored stools, unusual tiredness, weakness, stomach or abdominal pain, and loss of appetite as non-specific symptoms of liver disease. These are signs of liver injury that hospitals treat as urgent.
In the largest controlled kava trial (16 weeks, aqueous root extract), liver function test abnormalities were significantly more frequent in the kava group than on placebo, although no participant met criteria for herb-induced liver injury (Sarris 2020).
Key Research Papers
- Magura EI, Kopanitsa MV, Gleitz J, Peters T, Krishtal OA (1997). Kava extract ingredients, (+)-methysticin and (+/-)-kavain inhibit voltage-operated Na(+)-channels in rat CA1 hippocampal neurons. Neuroscience. — PubMed PMID: 9300426
- Friese J, Gleitz J (1998). Kavain, dihydrokavain, and dihydromethysticin non-competitively inhibit the specific binding of [3H]-batrachotoxinin-A 20-alpha-benzoate to receptor site 2 of voltage-gated Na+ channels. Planta Medica. — PubMed PMID: 9690349
- Gleitz J, Friese J, Beile A, Ameri A, Peters T (1996). Anticonvulsive action of (+/-)-kavain estimated from its properties on stimulated synaptosomes and Na+ channel receptor sites. European Journal of Pharmacology. — PubMed PMID: 8960869
- Schirrmacher K, Büsselberg D, Langosch JM, Walden J, Winter U, Bingmann D (1999). Effects of (+/-)-kavain on voltage-activated inward currents of dorsal root ganglion cells from neonatal rats. European Neuropsychopharmacology. — PubMed PMID: 10082244
- Davies LP, Drew CA, Duffield P, Johnston GA, Jamieson DD (1992). Kava pyrones and resin: studies on GABAA, GABAB and benzodiazepine binding sites in rodent brain. Pharmacology & Toxicology. — PubMed PMID: 1332016
- Singh YN (1983). Effects of kava on neuromuscular transmission and muscle contractility. Journal of Ethnopharmacology. — PubMed PMID: 6308355
- Singh YN (1992). Kava: an overview. Journal of Ethnopharmacology. — PubMed PMID: 1453702
- Spinella M (2002). The importance of pharmacological synergy in psychoactive herbal medicines. Alternative Medicine Review. — PubMed PMID: 11991792
- Backhauss C, Krieglstein J (1992). Extract of kava (Piper methysticum) and its methysticin constituents protect brain tissue against ischemic damage in rodents. European Journal of Pharmacology. — PubMed PMID: 1396990
- Walden J, von Wegerer J, Winter U, Berger M, Grunze H (1997). Effects of kawain and dihydromethysticin on field potential changes in the hippocampus. Progress in Neuro-Psychopharmacology & Biological Psychiatry. — PubMed PMID: 9194150
- Holm E, Staedt U, Heep J, Kortsik C, Behne F, Kaske A, Mennicke I (1991). The action profile of D,L-kavain. Cerebral sites and sleep-wakefulness-rhythm in animals (in German). Arzneimittel-Forschung. — PubMed PMID: 1772452
- Cropley M, Cave Z, Ellis J, Middleton RW (2002). Effect of kava and valerian on human physiological and psychological responses to mental stress assessed under laboratory conditions. Phytotherapy Research. — PubMed PMID: 11807960
- Sarris J, Byrne GJ, Bousman CA, Cribb L, Savage KM, Holmes O, Murphy J, Macdonald P, Short A, Nazareth S, Jennings E, Thomas SR, Ogden E, Chamoli S, Scholey A, Stough C (2020). Kava for generalised anxiety disorder: a 16-week double-blind, randomised, placebo-controlled study. Australian and New Zealand Journal of Psychiatry. — PubMed PMID: 31813230
- Smith SY, Aylwin CF, Daniels TF, Greer JL, Kunces LJ, Lili L, Phipps SM, Schmidt CM, Schmidt JC, Schmidt MA (2024). Kavalactones support motivation to move during intensive training in males preparing for military special operations forces. Journal of the International Society of Sports Nutrition. — PubMed PMID: 39010683
- U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition (2002). Consumer Advisory: Kava-Containing Dietary Supplements May be Associated With Severe Liver Injury. March 25, 2002. — FDA Consumer Advisory (archived)